{"product_id":"equine-clinical-immunology-isbn-9781118558874","title":"Equine Clinical Immunology","description":"\u003ci\u003eEquine Clinical Immunology\u003c\/i\u003e offers comprehensive information on equine immunological disorders.\u003cbr\u003e\u003cbr\u003e•     Provides a complete, equine-specific reference on clinical immunology \u003cbr\u003e•     Focuses on clinically relevant information for the diagnosis and treatment of horses with immune disorders \u003cbr\u003e•     Illustrates the concepts discussed using drawings, photographs, and tables \u003cbr\u003e•     Presents key concepts, clinical assessment information, and treatment approaches in text boxes for ease of use \u003cbr\u003e•     Offers a practical, clinically oriented approach ideal for equine specialists \u003cp\u003eContributors, ix\u003c\/p\u003e \u003cp\u003ePreface, xi\u003c\/p\u003e \u003cp\u003e\u003cb\u003e1 The Immune System, 1\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eM. Julia B. Felippe\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e1.1 Definition, 1\u003c\/p\u003e \u003cp\u003e1.2 The organs of the immune system, 1\u003c\/p\u003e \u003cp\u003e1.3 The immune cells and soluble molecules, 2\u003c\/p\u003e \u003cp\u003e1.4 B and T cell activation in lymphoid tissues, 6\u003c\/p\u003e \u003cp\u003e1.5 When the immune response goes wrong, 9\u003c\/p\u003e \u003cp\u003eReferences, 10\u003c\/p\u003e \u003cp\u003e\u003cb\u003e2 The Immune System of the Young Horse, 11\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eRebecca L. Tallmadge\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e2.1 Definition, 11\u003c\/p\u003e \u003cp\u003e2.2 Equine immune system development, 11\u003c\/p\u003e \u003cp\u003e2.3 Unique susceptibilities and disorders of young horses, 16\u003c\/p\u003e \u003cp\u003e2.4 Vaccinology teaches about neonatal immunity, 18\u003c\/p\u003e \u003cp\u003eReferences, 18\u003c\/p\u003e \u003cp\u003e\u003cb\u003e3 The Immune System of the Older Horse, 23\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eAmanda A. Adams and David W. Horohov\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3.1 Definition, 23\u003c\/p\u003e \u003cp\u003e3.2 Clinical conditions associated with aging, 23\u003c\/p\u003e \u003cp\u003e3.3 Immunosenescence and vaccination, 23\u003c\/p\u003e \u003cp\u003e3.4 Nutrition in enhancing immunity in the old horse, 26\u003c\/p\u003e \u003cp\u003e3.5 Conclusion, 27\u003c\/p\u003e \u003cp\u003eReferences, 27\u003c\/p\u003e \u003cp\u003e\u003cb\u003e4 Anaphylaxis, 31\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eRolfe M. Radcliffe\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e4.1 Definition, 31\u003c\/p\u003e \u003cp\u003e4.2 Signalment and clinical signs, 31\u003c\/p\u003e \u003cp\u003e4.3 Immunologic mechanisms and etiologic associations, 32\u003c\/p\u003e \u003cp\u003e4.4 Diagnostics, 33\u003c\/p\u003e \u003cp\u003e4.5 Treatment, 34\u003c\/p\u003e \u003cp\u003e4.6 Prevention, 36\u003c\/p\u003e \u003cp\u003e4.7 Prognosis and clinical outcomes, 37\u003c\/p\u003e \u003cp\u003eReferences, 37\u003c\/p\u003e \u003cp\u003e\u003cb\u003e5 Allergy, 39\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eBettina Wagner\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e5.1 Definition, 39\u003c\/p\u003e \u003cp\u003e5.2 Culicoides hypersensitivity, 39\u003c\/p\u003e \u003cp\u003e5.3 Urticaria, 43\u003c\/p\u003e \u003cp\u003e5.4 Recurrent airway obstruction, 44\u003c\/p\u003e \u003cp\u003eReferences, 44\u003c\/p\u003e \u003cp\u003e\u003cb\u003e6 Immune-Mediated Cytopenias, 47\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eThomas J. Divers\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e6.1 Definition, 47\u003c\/p\u003e \u003cp\u003e6.2 Immune-mediated hemolytic anemia, 47\u003c\/p\u003e \u003cp\u003e6.3 Immune-mediated thrombocytopenia, 50\u003c\/p\u003e \u003cp\u003e6.4 Immune-mediated neutropenia, 53\u003c\/p\u003e \u003cp\u003eReferences, 54\u003c\/p\u003e \u003cp\u003e\u003cb\u003e7 Bullous Diseases of the Skin and Mucosa, 55\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eJeanine Peters-Kennedy and Rebecca E. Ruby\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e7.1 Definition, 55\u003c\/p\u003e \u003cp\u003e7.2 Immune-mediated bullous dermatoses, 55\u003c\/p\u003e \u003cp\u003e7.3 Pemphigus complex, 57\u003c\/p\u003e \u003cp\u003e7.4 Cutaneous adverse drug reactions, 61\u003c\/p\u003e \u003cp\u003e7.5 Erythema multiforme, 62\u003c\/p\u003e \u003cp\u003e7.6 Lupus erythematosus, 64\u003c\/p\u003e \u003cp\u003eReferences, 65\u003c\/p\u003e \u003cp\u003e\u003cb\u003e8 Serum Sickness, 69\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eLais R.R. Costa\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e8.1 Definition, 69\u003c\/p\u003e \u003cp\u003e8.2 Signalment and clinical signs, 69\u003c\/p\u003e \u003cp\u003e8.3 Immunologic mechanisms and etiologic associations, 69\u003c\/p\u003e \u003cp\u003e8.4 Diagnostics, 71\u003c\/p\u003e \u003cp\u003e8.5 Treatment and prevention, 71\u003c\/p\u003e \u003cp\u003eReferences, 72\u003c\/p\u003e \u003cp\u003e\u003cb\u003e9 Vasculitis, 73\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eJames S. W. Prutton and Nicola Pusterla\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e9.1 Definition, 73\u003c\/p\u003e \u003cp\u003e9.2 Signalment and clinical signs, 73\u003c\/p\u003e \u003cp\u003e9.3 Immunologic mechanisms and etiologic associations, 73\u003c\/p\u003e \u003cp\u003e9.4 Diagnostics, 75\u003c\/p\u003e \u003cp\u003e9.5 Treatment, 75\u003c\/p\u003e \u003cp\u003e9.6 Thrombophlebitis, 75\u003c\/p\u003e \u003cp\u003e9.7 Pastern and cannon leukocytoclastic vasculitis, 76\u003c\/p\u003e \u003cp\u003e9.8 Drug-induced vasculitis, 76\u003c\/p\u003e \u003cp\u003e9.9 Photo-activated vasculitis (photodynamic drugs), 77\u003c\/p\u003e \u003cp\u003e9.10 Strongylus vulgaris, 77\u003c\/p\u003e \u003cp\u003e9.11 Equine granulocytic anaplasmosis, 77\u003c\/p\u003e \u003cp\u003e9.12 Equine viral arteritis, 78\u003c\/p\u003e \u003cp\u003e9.13 Equine herpesvirus-1, 78\u003c\/p\u003e \u003cp\u003e9.14 African horse sickness, 78\u003c\/p\u003e \u003cp\u003eReferences, 79\u003c\/p\u003e \u003cp\u003e\u003cb\u003e10 Purpura Hemorrhagica, 83\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eLaszlo M. Hunyadi and Nicola Pusterla\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e10.1 Definition, 83\u003c\/p\u003e \u003cp\u003e10.2 Signalment and clinical signs, 83\u003c\/p\u003e \u003cp\u003e10.3 Immunologic mechanisms and etiologic associations, 83\u003c\/p\u003e \u003cp\u003e10.4 Diagnostics, 84\u003c\/p\u003e \u003cp\u003e10.5 Treatment and prevention, 85\u003c\/p\u003e \u003cp\u003eReferences, 86\u003c\/p\u003e \u003cp\u003e\u003cb\u003e11 Glomerulonephritis, 87\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eM. Julia B. Felippe\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e11.1 Definition, 87\u003c\/p\u003e \u003cp\u003e11.2 Signalment and clinical signs, 87\u003c\/p\u003e \u003cp\u003e11.3 Immunologic mechanisms and etiologic associations, 87\u003c\/p\u003e \u003cp\u003e11.4 Diagnostics, 88\u003c\/p\u003e \u003cp\u003e11.5 Treatment and prognosis, 88\u003c\/p\u003e \u003cp\u003eReferences, 88\u003c\/p\u003e \u003cp\u003e\u003cb\u003e12 Inflammatory and Immune-Mediated Muscle Disorders, 91\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eSian Durward-Akhurst and Stephanie J. Valberg\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e12.1 Definition, 91\u003c\/p\u003e \u003cp\u003e12.2 Infarctive purpura hemorrhagica, 91\u003c\/p\u003e \u003cp\u003e12.3 Rhabdomyolysis associated with Streptococcus equi, 93\u003c\/p\u003e \u003cp\u003e12.4 Immune-mediated myositis in Quarter Horse-related breeds, 94\u003c\/p\u003e \u003cp\u003e12.5 Systemic calcinosis, 96\u003c\/p\u003e \u003cp\u003e12.6 Uncharacterized immune-mediated and inflammatory myopathies, 97\u003c\/p\u003e \u003cp\u003e12.7 Sarcocystis myositis, 97\u003c\/p\u003e \u003cp\u003eReferences, 98\u003c\/p\u003e \u003cp\u003e\u003cb\u003e13 Granulomatous Diseases, 101\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eLais R.R. Costa\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e13.1 Definition, 101\u003c\/p\u003e \u003cp\u003e13.2 Signalment and clinical signs, 101\u003c\/p\u003e \u003cp\u003e13.3 Immunologic mechanisms and etiologic associations, 101\u003c\/p\u003e \u003cp\u003e13.4 Diagnostics, 104\u003c\/p\u003e \u003cp\u003e13.5 Treatment and prevention, 105\u003c\/p\u003e \u003cp\u003e13.6 Types of cell-mediated hypersensitivity reactions, 105\u003c\/p\u003e \u003cp\u003eReferences, 110\u003c\/p\u003e \u003cp\u003e\u003cb\u003e14 Chronic Inflammatory Bowel Disease, 113\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eGillian A. Perkins\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e14.1 Definition, 113\u003c\/p\u003e \u003cp\u003e14.2 Signalment and clinical signs, 113\u003c\/p\u003e \u003cp\u003e14.3 Immunologic mechanisms and etiologic associations, 113\u003c\/p\u003e \u003cp\u003e14.4 Diagnostics, 115\u003c\/p\u003e \u003cp\u003e14.5 Treatment and prognosis, 116\u003c\/p\u003e \u003cp\u003eReferences, 117\u003c\/p\u003e \u003cp\u003e\u003cb\u003e15 Recurrent Uveitis, 121\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eBrian C. Gilger\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e15.1 Definition, 121\u003c\/p\u003e \u003cp\u003e15.2 Signalment and clinical signs, 121\u003c\/p\u003e \u003cp\u003e15.3 Immunologic mechanisms and etiologic associations, 121\u003c\/p\u003e \u003cp\u003e15.4 Diagnostics, 123\u003c\/p\u003e \u003cp\u003e15.5 Treatment and prevention, 124\u003c\/p\u003e \u003cp\u003e15.6 Prognosis and clinical outcomes, 124\u003c\/p\u003e \u003cp\u003eReferences, 125\u003c\/p\u003e \u003cp\u003e\u003cb\u003e16 Recurrent Airway Obstruction and Summer Pasture-Associated Obstructive Pulmonary Disease, 127\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eMichela Bullone and Jean-Pierre Lavoie\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e16.1 Definition, 127\u003c\/p\u003e \u003cp\u003e16.2 Signalment and clinical signs, 127\u003c\/p\u003e \u003cp\u003e16.3 Immunologic mechanisms and etiologic associations, 128\u003c\/p\u003e \u003cp\u003e16.4 Diagnostics, 134\u003c\/p\u003e \u003cp\u003e16.5 Treatments and prevention, 136\u003c\/p\u003e \u003cp\u003eReferences, 137\u003c\/p\u003e \u003cp\u003e\u003cb\u003e17 Inflammatory Airway Disease, 145\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eMathilde Leclère and Jean-Pierre Lavoie\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e17.1 Definition, 145\u003c\/p\u003e \u003cp\u003e17.2 Signalment and clinical signs, 145\u003c\/p\u003e \u003cp\u003e17.3 Immunologic mechanisms and etiologic associations, 145\u003c\/p\u003e \u003cp\u003e17.4 Types of bronchoalveolar lavage fluid inflammation and cytokine profile, 147\u003c\/p\u003e \u003cp\u003e17.5 Links between IAD and heaves, 148\u003c\/p\u003e \u003cp\u003e17.6 Links between IAD and EIPH, 148\u003c\/p\u003e \u003cp\u003e17.7 Diagnostics, 148\u003c\/p\u003e \u003cp\u003e17.8 Treatment and prevention, 149\u003c\/p\u003e \u003cp\u003e17.9 Prognosis and clinical outcomes, 150\u003c\/p\u003e \u003cp\u003eReferences, 150\u003c\/p\u003e \u003cp\u003e\u003cb\u003e18 Inflammation, Endotoxemia and Systemic Inflammatory Response Syndrome, 153\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eErin L. McConachie and Kelsey A. Hart\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e18.1 Definition, 153\u003c\/p\u003e \u003cp\u003e18.2 Signalment and clinical signs, 154\u003c\/p\u003e \u003cp\u003e18.3 Immunologic mechanisms and etiologic associations, 155\u003c\/p\u003e \u003cp\u003e18.4 Multi-systemic response triggered by inflammatory mediators, 157\u003c\/p\u003e \u003cp\u003e18.5 Diagnostics, 160\u003c\/p\u003e \u003cp\u003e18.6 Treatment, 162\u003c\/p\u003e \u003cp\u003e18.7 Prognosis and clinical outcome, 166\u003c\/p\u003e \u003cp\u003eReferences, 166\u003c\/p\u003e \u003cp\u003e\u003cb\u003e19 Leukemia, 173\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eTracy Stokol\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e19.1 Definition, 173\u003c\/p\u003e \u003cp\u003e19.2 Classification of leukemias, 173\u003c\/p\u003e \u003cp\u003e19.3 Specialized diagnostic techniques for leukemia, 173\u003c\/p\u003e \u003cp\u003e19.4 Chronic leukemia, 175\u003c\/p\u003e \u003cp\u003e19.5 Acute leukemia, 177\u003c\/p\u003e \u003cp\u003eReferences, 179\u003c\/p\u003e \u003cp\u003e\u003cb\u003e20 Lymphoma, 181\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eSallyAnne L. Ness\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e20.1 Definition, 181\u003c\/p\u003e \u003cp\u003e20.2 Signalment and clinical signs, 181\u003c\/p\u003e \u003cp\u003e20.3 Forms of equine lymphoma, 182\u003c\/p\u003e \u003cp\u003e20.4 Immunologic mechanisms and etiologic associations, 183\u003c\/p\u003e \u003cp\u003e20.5 Diagnostics, 183\u003c\/p\u003e \u003cp\u003e20.6 Classification of lymphomas, 185\u003c\/p\u003e \u003cp\u003e20.7 Prognosis and treatment, 186\u003c\/p\u003e \u003cp\u003e20.8 Monitoring, 189\u003c\/p\u003e \u003cp\u003eReferences, 189\u003c\/p\u003e \u003cp\u003e\u003cb\u003e21 Immunodeficiencies, 193\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eM. Julia B. Felippe\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e21.1 Definition, 193\u003c\/p\u003e \u003cp\u003e21.2 Classification of immunodeficiencies, 194\u003c\/p\u003e \u003cp\u003eReferences, 202\u003c\/p\u003e \u003cp\u003e\u003cb\u003e22 Immunologic Testing, 205\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eM. Julia B. Felippe\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e22.1 Definition, 205\u003c\/p\u003e \u003cp\u003e22.2 Types of immunologic testing, 205\u003c\/p\u003e \u003cp\u003eReferences, 211\u003c\/p\u003e \u003cp\u003e\u003cb\u003e23 Non-steroidal Anti-inflammatories, 213\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eMichelle H. Barton\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e23.1 Definition, 213\u003c\/p\u003e \u003cp\u003e23.2 Non-steroidal anti-inflammatory drugs, 213\u003c\/p\u003e \u003cp\u003eReferences, 228\u003c\/p\u003e \u003cp\u003e\u003cb\u003e24 Immunosuppressive Therapy, 237\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eM. Julia B. Felippe\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e24.1 Definition, 237\u003c\/p\u003e \u003cp\u003e24.2 Types of immunosuppressive drugs, 237\u003c\/p\u003e \u003cp\u003eReferences, 240\u003c\/p\u003e \u003cp\u003e\u003cb\u003e25 Immunomodulators, 243\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eElizabeth G. Davis\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e25.1 Definition, 243\u003c\/p\u003e \u003cp\u003e25.2 Immunologic mechanisms, 243\u003c\/p\u003e \u003cp\u003e25.3 Commercially available immunostimulants for use in horses, 244\u003c\/p\u003e \u003cp\u003eReferences, 249\u003c\/p\u003e \u003cp\u003e\u003cb\u003e26 Immunoglobulin Therapy, 251\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eElizabeth G. Davis\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e26.1 Definition, 251\u003c\/p\u003e \u003cp\u003e26.2 Immunologic mechanisms, 251\u003c\/p\u003e \u003cp\u003eReferences, 254\u003c\/p\u003e \u003cp\u003e\u003cb\u003e27 Plasmapheresis, 257\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eNathan M. Slovis\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e27.1 Definition, 257\u003c\/p\u003e \u003cp\u003e27.2 Methods for preparing plasma products, 257\u003c\/p\u003e \u003cp\u003e27.3 Apheresis, 258\u003c\/p\u003e \u003cp\u003e27.4 Therapeutic plasmapheresis, 258\u003c\/p\u003e \u003cp\u003e27.5 Complications of therapeutic plasmapheresis, 260\u003c\/p\u003e \u003cp\u003eReferences, 260\u003c\/p\u003e \u003cp\u003e\u003cb\u003e28 Principles of Vaccination, 263\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eNoah D. Cohen and Angela I. Bordin\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e28.1 Definition, 263\u003c\/p\u003e \u003cp\u003e28.2 Efficacy and effectiveness of vaccines, 263\u003c\/p\u003e \u003cp\u003e28.3 Safety of vaccines, 271\u003c\/p\u003e \u003cp\u003e28.4 Key knowledge-gaps in equine vaccinology, 273\u003c\/p\u003e \u003cp\u003e28.5 Protocols for vaccination, 275\u003c\/p\u003e \u003cp\u003eReferences, 276\u003c\/p\u003e \u003cp\u003e\u003cb\u003e29 Types of Vaccines, 279\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eAngela I. Bordin and Noah D. Cohen\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e29.1 Definition, 279\u003c\/p\u003e \u003cp\u003e29.2 Immunologic mechanisms, 279\u003c\/p\u003e \u003cp\u003e29.3 Immune responses to vaccination, 282\u003c\/p\u003e \u003cp\u003e29.4 Routes of vaccination, 284\u003c\/p\u003e \u003cp\u003e29.5 Adjuvants and vaccine delivery systems, 285\u003c\/p\u003e \u003cp\u003e29.6 Important diseases with unavailable effective vaccines, 285\u003c\/p\u003e \u003cp\u003eReferences, 286\u003c\/p\u003e \u003cp\u003e\u003cb\u003e30 Transplantation Immunology, 289\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eRebecca L. Tallmadge\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e30.1 Definition, 289\u003c\/p\u003e \u003cp\u003e30.2 Equine MHC genes: genomic organization and variation, 289\u003c\/p\u003e \u003cp\u003e30.3 Determining equine MHC haplotypes, 290\u003c\/p\u003e \u003cp\u003e30.4 Immunosuppression and engraftment, 291\u003c\/p\u003e \u003cp\u003e30.5 Graft rejection, 292\u003c\/p\u003e \u003cp\u003e30.6 Current transplantation applications, 293\u003c\/p\u003e \u003cp\u003eReferences, 294\u003c\/p\u003e \u003cp\u003e\u003cb\u003e31 Mesenchymal Stem Cell Therapy, 297\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eGerlinde R. Van de Walle, Catharina De Schauwer and Lisa A. Fortier\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e31.1 Definition, 297\u003c\/p\u003e \u003cp\u003e31.2 Regenerative functions of mesenchymal stem cells, 297\u003c\/p\u003e \u003cp\u003e31.3 Immunologic mechanisms and associations, 298\u003c\/p\u003e \u003cp\u003e31.4 Sources of equine mesenchymal stem cells, 299\u003c\/p\u003e \u003cp\u003e31.5 Characterization of equine mesenchymal stem cells, 300\u003c\/p\u003e \u003cp\u003e31.6 Applications of equine mesenchymal stem cells in equine regenerative medicine, 302\u003c\/p\u003e \u003cp\u003eReferences, 306\u003c\/p\u003e \u003cp\u003e\u003cb\u003e32 Hematopoietic Stem Cell Transplantation, 311\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eM. Julia B. Felippe\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e32.1 Definition, 311\u003c\/p\u003e \u003cp\u003e32.2 Hematopoietic stem cell sources, 311\u003c\/p\u003e \u003cp\u003e32.3 Pre-transplantation conditioning, 313\u003c\/p\u003e \u003cp\u003e32.4 Post-transplantation immunosuppression, 313\u003c\/p\u003e \u003cp\u003e32.5 Hematopoietic stem cell transplantation in the horse, 313\u003c\/p\u003e \u003cp\u003eReferences, 315\u003c\/p\u003e \u003cp\u003eIndex, 317\u003c\/p\u003e \u003cp\u003e\u003cb\u003eM. Julia B. Felippe\u003c\/b\u003e, MedVet, MSc, PhD, DACVIM, is an Associate Professor of Large Animal Medicine and Veterinary Curriculum Director at Cornell University’s College of Veterinary Medicine in Ithaca, New York, USA.\u003c\/p\u003e \u003cp\u003e\u003ci\u003eEquine Clinical Immunology \u003c\/i\u003eoffers comprehensive information on equine immunological disorders.  Focusing specifically on diagnosing, treating, and managing conditions of the immune system in horses, the book is edited by a leading clinician in this area and contributed to by top experts in equine immunology.  Offering a practical, clinically oriented approach, \u003ci\u003eEquine Clinical Immunology\u003c\/i\u003e covers topics ranging from basic immunology and pathophysiology to specific immune disorders, testing, vaccination, and stem cell therapy. \u003c\/p\u003e \u003cp\u003eDesigned to present a complete resource on the topic, the book uses illustrations, photographs, and tables to explain the concepts discussed.  Text boxes provide key concepts, clinical assessment, and treatment approaches.  \u003ci\u003eEquine Clinical Immunology\u003c\/i\u003e offers a valuable resource for equine specialists seeking information related to immune disorders in equine patients.  \u003c\/p\u003e \u003cp\u003e\u003cb\u003eKey features \u003cbr\u003e\u003c\/b\u003e\u003c\/p\u003e \u003cul\u003e \u003cli\u003eProvides a complete, equine-specific reference on clinical immunology\u003c\/li\u003e \u003cli\u003eFocuses on clinically relevant information for the diagnosis and treatment of horses with immune disorders\u003c\/li\u003e \u003cli\u003eIllustrates the concepts discussed using drawings, photographs, and tables\u003c\/li\u003e \u003cli\u003ePresents key concepts, clinical assessment information, and treatment approaches in text boxes for ease of use\u003c\/li\u003e \u003cli\u003eOffers a practical, clinically oriented approach ideal for equine specialists\u003c\/li\u003e \u003c\/ul\u003e","brand":"Wiley-Blackwell","offers":[{"title":"Default Title","offer_id":47989151465701,"sku":"NP9781118558874","price":163.95,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1842\/7735\/files\/9781118558874.jpg?v=1761783003","url":"https:\/\/k12savings.com\/es\/products\/equine-clinical-immunology-isbn-9781118558874","provider":"K12savings","version":"1.0","type":"link"}